CARL B. LAUTER, M.D.
This content is PDF only. Please click on the PDF icon to access.
Herpes simplex encephalitis is a much more important disease than its prevalence would otherwise indicate (1, 2). It carries a 70% to 80% mortality in the first 30 days and a 90% mortality by 4 to 6 months (3). Vidarabine, in a dosage of 15 mg/kg per day, given intravenously for 10 days, markedly improves the outcome if administered to the patient early in the course and before the occurrence of coma (2). Patients with herpes simplex encephalitis who are treated early have a mortality rate of 32% at 30 days and 41% by 4 months (3). Morbidity is also
LAUTER CB. Herpes Simplex Encephalitis: A Great Clinical Challenge. Ann Intern Med. ;92:696–698. doi: 10.7326/0003-4819-92-5-696
Download citation file:
Published: Ann Intern Med. 1980;92(5):696-698.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use